This Announcement
contains inside information for the purposes of Article 7
of the Market Abuse Regulation No. 596/2014 as retained as
part of UK law by virtue of the European Union (Withdrawal) Act
2018 as amended ("EUWA") and as it may
be modified from time to time by or under domestic law
including, but not limited to, by the Market Abuse (Amendment) (EU
Exit) Regulations 2019/310). Upon the publication of this
Announcement, this inside information is now considered to be in
the public domain.
17
December 2024
4basebio
PLC
("4basebio" or the
"Company")
Directorate
Change
17 December 2024 - 4basebio PLC (AIM:
4BB) (“4basebio” or the
“Company”), which develops and commercialises the
large scale manufacture of synthetic DNA as well as nanoparticle
delivery solutions, announces the appointment of Alan Malus as
Independent Non-executive Director of the Company, as of
16 December
2024.
Mr. Alan Joseph Malus,
Independent Non-executive
Director
Mr. Malus has over 18
years of experience in life sciences and diagnostics, having most
recently served as Corporate Executive Vice President and President
of the Laboratory Products and Services Segment at Thermo Fisher
Scientific. He joined Thermo Fisher
in 1998, holding numerous executive positions including President
Analytical Technologies Group, President Lab Products Group, and
President Customer Chanels Group. Prior to this, Mr. Malus spent
nearly 15 years in the automotive industry, working with Ford,
Chrysler, and Textron Inc., where he served as Vice President of
Finance.
Since 2023, Mr. Malus has
been a Director at Industrial Physics Inc. He also serves as
Director at Azenta Life Sciences. Previously, he served as a
Director at PHC Holdings Corporation in Japan (2021 to 2022).
Mr. Malus graduated from
the University of Michigan in 1981,
starting his career as a financial analyst at Ford in 1984 and
moving to Chrysler in 1986.
Pursuant to Rule 17 and
Schedule 2(g) of the AIM Rules for Companies, the following
information is disclosed in respect of Mr. Alan Joseph Malus (aged
65):
|
Current
Directorships |
Previous
Directorships held in the past five
years |
|
USA |
Japan |
|
Azenta
Inc. |
PHC Holdings
Corporation |
|
Industrial Physics,
Inc |
|
Mr. Malus holds no
Ordinary Shares, and no options or warrants over Ordinary
Shares. There is no further information regarding Mr. Malus
that is required to be disclosed under the AIM
Rules.
Enquiries
|
4basebio
PLC
Dr. Heikki
Lanckriet
|
+44 (0)1223 967
943
|
|
Nominated
Adviser
Cairn Financial
Advisers LLP
Jo Turner / Sandy Jamieson
/ Ed Downes
|
+44 (0)20 7213
0880
|
|
Joint
Broker
RBC Capital
Markets
Rupert Walford / Max
Avison / Kathryn Deegan
|
+44 (0)20 7653
4000
|
|
Joint
Broker
Cavendish Capital
Markets Limited
Geoff Nash / Nigel
Birks
|
+44 (0)20 7220
0500
|
Notes to
Editors
About
4basebio
4basebio (AIM: 4BB) is an
innovation driven life biotechnology company focused on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high-performance synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company’s objective is to become a market leader in the manufacture
and supply of high-quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in
patients.